14
Diagnosis
(cont'd)
Table 2. Selected Genetic Alterations Linked to FDA
Approvals as of June 2021
a
Genetic Alterations Tumor type Targeted Therapeutics
FDA-listed genetic alterations contraindicated for specific treatments
KRAS and/or NRAS
exon 2, 3, and 4
mutations
Colorectal cancer Panitumumab, Cetuximab
NTRK1 and NTRK3
known acquired
resistance mutations
(e.g., NTRK1 G595R
and G667C; NTRK3
F617L, G623R, and
G696A)
Solid tumors Entrectinib, Larotrectinib
FDA-approved combination treatments with non-targeted therapies for specific
genetic alterations
BRAF V600
Melanoma Atezolizumab + Cobimetinib +
Vemurafenib
Deleterious germline
and/or somatic
mutations in BRCA1 or
BRCA2
Fallopian tube, ovarian,
primary peritoneal
carcinoma
Bevacizumab + Olaparib
EGFR exon 19
deletions, L858R
NSCLC Erlotinib + Ramucirumab
ERBB2 amplification
Breast cancer • Hyaluronidase-zzxf /
Pertuzumab / Trastuzumab +
Chemotherapy (Docetaxel)
• Trastuzumab + Pertuzumab +
Chemotherapy (Docetaxel)
• Trastuzumab + (Docetaxel +
Carboplatin) or (Doxorubicin
+ Cyclophosphamide +
Paclitaxel or Docetaxel) or
Paclitaxel
• Lapatinib + Capecitabine or
Letrozole
• Neratinib + Capecitabine
• Margetuximab +
Chemotherapy
Esophagogastric cancer Trastuzumab + Cisplatin +
Capecitabine or 5-fluorouracil
a
e table summarizes FDA approvals at data cut-off of June 2, 2021. Precision oncology is a rapidly
evolving field, and this table is a static snapshot of the approved targeted therapies at a specific point
in time and therefore is expected to be outdated beyond the date it was published. e table is being
included to provide examples of approved agents linked to genomic biomarkers or in disease with
common genomic drivers.
(cont'd)
